Indian Weight-Loss Drug Market to Expand with Semaglutide Generics Post-Patent Expiry

The Indian market for GLP-1 and weight-loss drugs, including semaglutide, is expected to grow fivefold to Rs 5,000 crore by 2030, driven by type-2 diabetes and obesity treatment. Following semaglutide's patent expiry in March 2024, prices are projected to decline significantly due to increased competition and trade agreements. Mankind Pharma aims to be among the first to launch generic semaglutide in India, focusing on affordability and accessibility while navigating challenges like patent litigations and manufacturing complexities.